TY - JOUR
T1 - Insomnia Symptoms and Daytime Fatigue Co-Occurrence in Adolescent and Young Adult Childhood Cancer Patients in Follow-Up after Treatment
T2 - Prevalence and Associated Risk Factors
AU - Peersmann, Shosha H M
AU - Grootenhuis, Martha A
AU - van Straten, Annemieke
AU - Tissing, Wim J E
AU - Abbink, Floor
AU - de Vries, Andrica C H
AU - Loonen, Jacqueline
AU - van der Pal, Helena J H
AU - Kaspers, Gertjan J L
AU - van Litsenburg, Raphaële R L
N1 - Publisher Copyright:
© 2022 by the authors. icensee MDPI, Basel, Switzerland.
PY - 2022/7/7
Y1 - 2022/7/7
N2 - Insomnia symptoms and daytime fatigue commonly occur in pediatric oncology, which significantly impact physical and psychosocial health. This study evaluated the prevalence of insomnia only, daytime fatigue only, the co-occurrence of insomnia–daytime fatigue symptoms, and associated risk factors. Childhood cancer patients (n = 565, 12–26 years old, ≥6 months after treatment) participated in a national, cross-sectional questionnaire study, measuring insomnia symptoms (ISI; Insomnia Severity Index) and daytime fatigue (single item). Prevalence rates of insomnia and/or daytime fatigue subgroups and ISI severity ranges were calculated. Multinomial regression models were applied to assess risk factors. Most patients reported no insomnia symptoms or daytime fatigue (61.8%). In the 38.2% of patients who had symptoms, 48.1% reported insomnia and daytime fatigue, 34.7% insomnia only, and 17.1% daytime fatigue only. Insomnia scores were higher in patients with insomnia–daytime fatigue compared to insomnia only (p < 0.001). Risk factors that emerged were: female sex and co-morbidities (all), shorter time after treatment and bedtime gaming (insomnia only), young adulthood (insomnia–fatigue/fatigue only), needing someone else to fall asleep and inconsistent wake times (both insomnia groups), lower educational level and consistent bedtimes (insomnia–fatigue). Insomnia symptoms and daytime fatigue are common and often co-occur. While current fatigue guidelines do not include insomnia symptoms, healthcare providers should inquire about insomnia as this potentially provides additional options for treatment and prevention.
AB - Insomnia symptoms and daytime fatigue commonly occur in pediatric oncology, which significantly impact physical and psychosocial health. This study evaluated the prevalence of insomnia only, daytime fatigue only, the co-occurrence of insomnia–daytime fatigue symptoms, and associated risk factors. Childhood cancer patients (n = 565, 12–26 years old, ≥6 months after treatment) participated in a national, cross-sectional questionnaire study, measuring insomnia symptoms (ISI; Insomnia Severity Index) and daytime fatigue (single item). Prevalence rates of insomnia and/or daytime fatigue subgroups and ISI severity ranges were calculated. Multinomial regression models were applied to assess risk factors. Most patients reported no insomnia symptoms or daytime fatigue (61.8%). In the 38.2% of patients who had symptoms, 48.1% reported insomnia and daytime fatigue, 34.7% insomnia only, and 17.1% daytime fatigue only. Insomnia scores were higher in patients with insomnia–daytime fatigue compared to insomnia only (p < 0.001). Risk factors that emerged were: female sex and co-morbidities (all), shorter time after treatment and bedtime gaming (insomnia only), young adulthood (insomnia–fatigue/fatigue only), needing someone else to fall asleep and inconsistent wake times (both insomnia groups), lower educational level and consistent bedtimes (insomnia–fatigue). Insomnia symptoms and daytime fatigue are common and often co-occur. While current fatigue guidelines do not include insomnia symptoms, healthcare providers should inquire about insomnia as this potentially provides additional options for treatment and prevention.
KW - Adolescents and young adults (AYA)
KW - Childhood cancer
KW - Fatigue
KW - Quality of life
KW - Sleep
KW - Survivors
KW - Adolescents and young adults (AYA)
KW - Childhood cancer
KW - Fatigue
KW - Quality of life
KW - Sleep
KW - Survivors
UR - http://www.scopus.com/inward/record.url?scp=85137727471&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/571605de-9cf3-3e5a-8682-737a8097517a/
U2 - 10.3390/cancers14143319
DO - 10.3390/cancers14143319
M3 - Article
C2 - 35884378
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 14
ER -